NHS England is considering evidence which could lead to the commissioning of a new treatment for adults with Von Willebrand Disease.
NHS England believes it has seen enough research from NICE (the National Institute for Health and Care Excellence) to consider making vonicog alpha routinely available and is now looking for feedback from adults with VWD and stakeholders.
The treatment vonicog alpha works in the body in the same way as von Willebrand factor made by the body itself, by replacing the protein needed to stop bleeding that is missing or not working. Vonicog alpha has been artificially made rather than taking it from human blood.
It would be used on adults for treating bleeding complications or given before surgery for preventing bleeding. This would be an alternative treatment option to plasma derived concentrates for an adult with VWD.
The consultation documents are available here
You can complete the survey, which is open until 18 September, by following this link
If you have any questions, please contact us email@example.com